Replies to post #156006 on Biotech Values

[DewDiligence]

25-year saga of Lemtrada for MS may be nearing a successful completion:

http://in.reuters.com/article/2013/06/10/us-sanofi-lemtrada-idINBRE9590L320130610

The drug's quarter-century journey from a laboratory in Cambridge, England, to a possible $1 billion-a-year seller has involved a string of pass-the-parcel deals that serve as an object lesson in complex "drug dealing" between rival companies.

The chain of Lemtrada/Campath ownership has been: University of Cambridge, British Technology Group, GSK, BTG (again), Leukocyte, MLNM (via acquisition of Leukocyte), Ilex Oncology, Genzyme (via acquisition of Ilex), SNY (via acquisition of GENZ).

The CHMP could rule on SNY’s MAA by the end of June. The FDA PDUFA date is in late 2013 (#msg-83916470); the original PDUFA date in Apr 2013 was derailed by an RTF letter in 2012 (#msg-78944040).

p.s. I question anyone who projects as much as $1B in peak sales for Lemtrada in MS.